vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Howard Hughes Holdings Inc. (HHH). Click either name above to swap in a different company.
Howard Hughes Holdings Inc. is the larger business by last-quarter revenue ($235.9M vs $139.2M, roughly 1.7× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 3.4%, a 32.1% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -13.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Howard Hughes Holdings Inc., formerly the Howard Hughes Corporation, is a real estate development and management company based in The Woodlands, Texas. It was formed in 2010 as a spin-off from General Growth Properties (GGP). Most of its holdings are focused on several master-planned communities. It took its name from the original Howard Hughes Corporation, which had developed the planned community of Summerlin, Nevada, and later became a subsidiary of GGP.
ADMA vs HHH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $235.9M |
| Net Profit | $49.4M | $8.1M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 121.6% |
| Net Margin | 35.5% | 3.4% |
| Revenue YoY | 18.4% | 18.4% |
| Net Profit YoY | -55.9% | -25.6% |
| EPS (diluted) | $0.20 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $235.9M | ||
| Q4 25 | $139.2M | $624.4M | ||
| Q3 25 | $134.2M | $390.2M | ||
| Q2 25 | $122.0M | $260.9M | ||
| Q1 25 | $114.8M | $199.3M | ||
| Q4 24 | $117.5M | $935.0M | ||
| Q3 24 | $119.8M | $327.1M | ||
| Q2 24 | $107.2M | $317.4M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $49.4M | $6.0M | ||
| Q3 25 | $36.4M | $119.5M | ||
| Q2 25 | $34.2M | $-12.1M | ||
| Q1 25 | $26.9M | $10.5M | ||
| Q4 24 | $111.9M | $156.3M | ||
| Q3 24 | $35.9M | $72.8M | ||
| Q2 24 | $32.1M | $21.1M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | 121.6% | ||
| Q4 25 | 45.1% | 4.2% | ||
| Q3 25 | 38.0% | 48.6% | ||
| Q2 25 | 35.1% | 26.0% | ||
| Q1 25 | 30.4% | 24.0% | ||
| Q4 24 | 32.6% | 33.5% | ||
| Q3 24 | 33.1% | 60.6% | ||
| Q2 24 | 36.6% | 20.4% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | 35.5% | 1.0% | ||
| Q3 25 | 27.1% | 30.6% | ||
| Q2 25 | 28.1% | -4.7% | ||
| Q1 25 | 23.4% | 5.3% | ||
| Q4 24 | 95.2% | 16.7% | ||
| Q3 24 | 30.0% | 22.2% | ||
| Q2 24 | 29.9% | 6.6% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.20 | $0.20 | ||
| Q3 25 | $0.15 | $2.02 | ||
| Q2 25 | $0.14 | $-0.22 | ||
| Q1 25 | $0.11 | $0.21 | ||
| Q4 24 | $0.45 | $3.14 | ||
| Q3 24 | $0.15 | $1.46 | ||
| Q2 24 | $0.13 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $1.8B |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $3.8B |
| Total Assets | $624.2M | $11.2B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $87.6M | $1.5B | ||
| Q3 25 | $61.4M | $1.5B | ||
| Q2 25 | $90.3M | $1.4B | ||
| Q1 25 | $71.6M | $493.7M | ||
| Q4 24 | $103.1M | $596.1M | ||
| Q3 24 | $86.7M | $400.7M | ||
| Q2 24 | $88.2M | $436.8M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | $5.1B | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $5.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $3.8B | ||
| Q4 25 | $477.3M | $3.8B | ||
| Q3 25 | $431.2M | $3.8B | ||
| Q2 25 | $398.3M | $3.6B | ||
| Q1 25 | $373.4M | $2.8B | ||
| Q4 24 | $349.0M | $2.8B | ||
| Q3 24 | $231.9M | $2.6B | ||
| Q2 24 | $188.3M | $3.0B |
| Q1 26 | — | $11.2B | ||
| Q4 25 | $624.2M | $10.6B | ||
| Q3 25 | $568.7M | $10.7B | ||
| Q2 25 | $558.4M | $10.3B | ||
| Q1 25 | $510.6M | $9.3B | ||
| Q4 24 | $488.7M | $9.2B | ||
| Q3 24 | $390.6M | $9.4B | ||
| Q2 24 | $376.4M | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | 1.35× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 1.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $360.3M | ||
| Q3 25 | $13.3M | $149.8M | ||
| Q2 25 | $21.1M | $177.3M | ||
| Q1 25 | $-19.7M | $-224.9M | ||
| Q4 24 | $50.2M | $337.1M | ||
| Q3 24 | $25.0M | $248.3M | ||
| Q2 24 | $45.6M | $-17.5M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $348.6M | ||
| Q3 25 | $-1.1M | $137.7M | ||
| Q2 25 | $18.7M | $169.7M | ||
| Q1 25 | $-24.4M | $-238.4M | ||
| Q4 24 | $47.5M | $317.1M | ||
| Q3 24 | $24.0M | $238.7M | ||
| Q2 24 | $43.6M | $-25.1M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 55.8% | ||
| Q3 25 | -0.8% | 35.3% | ||
| Q2 25 | 15.3% | 65.1% | ||
| Q1 25 | -21.2% | -119.6% | ||
| Q4 24 | 40.4% | 33.9% | ||
| Q3 24 | 20.0% | 73.0% | ||
| Q2 24 | 40.7% | -7.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 1.9% | ||
| Q3 25 | 10.7% | 3.1% | ||
| Q2 25 | 2.0% | 2.9% | ||
| Q1 25 | 4.1% | 6.8% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 0.9% | 2.9% | ||
| Q2 24 | 1.9% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 60.04× | ||
| Q3 25 | 0.36× | 1.25× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -21.35× | ||
| Q4 24 | 0.45× | 2.16× | ||
| Q3 24 | 0.70× | 3.41× | ||
| Q2 24 | 1.42× | -0.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
HHH
| Rental revenue | $113.5M | 48% |
| Master Planned Communities land sales | $99.6M | 42% |
| Other revenues | $11.0M | 5% |
| Builder price participation | $8.7M | 4% |
| Condominium rights and unit sales | $3.1M | 1% |
